Phathom Pharmaceuticals, Inc.
PHAT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001783183
No open-market purchases or sales by Phathom Pharmaceuticals, Inc. insiders were filed in the last 90 days; 161 institutions reported holding it in 13F filings for Q2 2026, worth $782.1M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Phathom Pharmaceuticals, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 117
- +8 vs. Q3 2023
- Shares held
- 54.1M
- +11.2M (+26.1%) vs. Q3 2023
- Total value
- $503.3M
- +$59.4M (+13.4%) vs. Q3 2023
- New holders
- 25
- 50 more added
- Sold out
- 17
- 22 more reduced
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PHAT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 161 | $782.1M |
| Q1 2026 | 174 | $765.5M |
| Q4 2025 | 173 | $1.03B |
| Q3 2025 | 133 | $733.6M |
| Q2 2025 | 117 | $550.5M |
| Q1 2025 | 137 | $401.4M |
| Q4 2024 | 144 | $541.2M |
| Q3 2024 | 133 | $1.31B |
| Q2 2024 | 114 | $598.6M |
| Q1 2024 | 114 | $588.2M |
| Q4 2023 | 117 | $503.3M |
| Q3 2023 | 110 | $452.7M |
| Q2 2023 | 103 | $612.6M |
| Q1 2023 | 84 | $219.7M |
| Q4 2022 | 87 | $316.6M |
| Q3 2022 | 94 | $334.3M |
| Q2 2022 | 94 | $230.0M |
| Q1 2022 | 82 | $349.1M |
| Q4 2021 | 83 | $562.0M |
| Q3 2021 | 84 | $819.8M |
| Q2 2021 | 79 | $843.6M |
| Q1 2021 | 84 | $919.2M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Phathom Pharmaceuticals, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| State Street Corp | 687,837 | $6.28M | 0.00% | +20,241+3.0% | Added |
| Catalys Pacific, LLC | 721,962 | $6.59M | 6.18% | +721,962 | New |
| Geode Capital Management, LLC | 735,273 | $6.71M | 0.00% | +52,703+7.7% | Added |
| Decheng Capital LLC | 850,000 | $7.76M | 2.17% | +850,000 | New |
| Woodline Partners LP | 1,096,121 | $10.0M | 0.11% | +356,100+48.1% | Added |
| 683 Capital Management, LLC | 1,280,000 | $11.7M | 1.17% | +180,000+16.4% | Added |
| Gilder Gagnon Howe & Co LLC | 1,455,132 | $13.3M | 0.18% | +145,084+11.1% | Added |
| Avidity Partners Management LP | 1,721,580 | $15.7M | 0.60% | +104,280+6.4% | Added |
| Vanguard Group Inc | 1,956,429 | $17.9M | 0.00% | +33,767+1.8% | Added |
| NEA Management Company, LLC | 1,960,169 | $17.9M | 1.19% | +683,574+53.5% | Added |
| Ensign Peak Advisors, Inc | 2,280,000 | $20.8M | 0.04% | +547,828+31.6% | Added |
| BlackRock Inc. | 2,678,891 | $24.5M | 0.00% | +241,149+9.9% | Added |
| Invesco Ltd. | 3,167,653 | $28.9M | 0.01% | −251,306−7.4% | Reduced |
| Carlyle Group Inc. | 3,496,808 | $31.9M | 1.54% | 00.0% | Unchanged |
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $34.3M | 11.59% | 00.0% | Unchanged |
| Takeda Pharmaceutical Co Ltd | 7,459,286 | $77.4M | 23.62% | +7,459,286 | New |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $92.3M | 4.93% | 00.0% | Unchanged |
| Altium Capital Management LP | 0 | $0 | 0.00% | −220,000−100.0% | Sold out |
| AlphaCentric Advisors LLC | 0 | $0 | 0.00% | −160,000−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −121,892−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −82,148−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −58,825−100.0% | Sold out |
| Hennion & Walsh Asset Management, Inc. | 0 | $0 | 0.00% | −48,987−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −18,815−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −17,008−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −14,847−100.0% | Sold out |
| Engineers Gate Manager LP | 0 | $0 | 0.00% | −12,888−100.0% | Sold out |
| Centiva Capital, LP | 0 | $0 | 0.00% | −10,962−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −2,120−100.0% | Sold out |
| Headinvest, LLC | 0 | $0 | 0.00% | −882−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −132−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −113−100.0% | Sold out |
| Newbridge Financial Services Group, Inc. | 0 | $0 | 0.00% | −35−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Decheng Capital Management III (Cayman), LLC | – | – | – | – | Not filed |